Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi, 2020
 
IRCT20180725040596N2
RCTumifenovir (arbidol)lopinavir/ritonavirCOVID 19 hospitalizedsome concern
50/50 inconclusive

    COVID 19 all comers meta-analysis

    ELACOI (Standard of care), 2020
     
    NCT04252885
    RCTumifenovir (arbidol)standard of careCOVID 19 all comerssome concern
    16/7 inconclusive

      COVID-19 mild to moderate meta-analysis

      ELACOI (Lopinavir/ritonavir), 2020
       
      NCT04252885
      RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
      35/34 inconclusive
      • inconclusive 84 % increase in PCR-negative conversion (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • inconclusive 8 % increase in PCR-negative conversion (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).